Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics develops therapies intended to address underlying causes of heart disease, with a clinical-stage pipeline led by TN-201 and TN-401 gene therapies. TN-201 is an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Company news commonly covers clinical data from the MyPEAK-1 and RIDGE-1 studies, financial results, cardiovascular research collaborations, and preclinical work supporting TN-301, a highly selective HDAC6 inhibitor studied for heart failure and related cardio/muscular disease. Updates also reference Tenaya’s target identification and validation capabilities, including iPSC-derived cardiomyocytes, engineered heart tissue models and in vivo disease models.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotechnology company focused on heart disease, announces CEO Faraz Ali's participation in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. He will engage in a fireside chat on April 24, 2023, at 1:30 PM ET, followed by a panel discussion titled Gene Therapy: Positioning for CMC Success at Every Stage on April 25, 2023, at 12:00 PM ET. A webcast of the fireside chat will be available on Tenaya's website. Tenaya focuses on developing therapies for genetic cardiovascular disorders, including leading candidates like TN-201 for HCM and TN-401 for ARVC.
Tenaya Therapeutics, Inc. (TNYA) announced it is well-capitalized for 2023 with a cash position of $204 million, enabling operations into 2025. In January, the FDA cleared its TN-201 gene therapy for MYBPC3-associated HCM, with a Phase 1b trial to begin in Q3 2023. Dosing has commenced for TN-301, a small molecule for heart failure, with data expected in H2 2023. The company plans to submit an IND for TN-401 in the same timeframe. For 2022, Tenaya recorded a net loss of $123.7 million and significant R&D expenses, totaling $94.5 million.
Tenaya Therapeutics (NASDAQ: TNYA) has announced its participation in two significant industry conferences: the SVB Securities Global Biopharma Conference and Cowen’s 43rd Annual Health Care Conference. The company presentation at the SVB conference is scheduled for February 16, 2023, from 1:00 PM ET to 1:30 PM ET. Additionally, Tenaya will engage in a Genetic Medicines Panel at Cowen’s conference on March 6, 2023, from 10:30 AM ET to 11:30 AM ET. Webcasts for both events will be available on the Investors section of Tenaya’s website. The company aims to address heart disease through innovative therapies.
Tenaya Therapeutics (TNYA) announced the FDA's clearance for its IND application to start clinical trials for TN-201, aimed at treating hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations. The Phase 1b trial will dose patients beginning Q3 2023, with initial data expected in 2024. Tenaya is also advancing its TN-301 and TN-401 programs, with milestones projected for 2023. The company has extended its cash runway into the first half of 2025, supported by a strong cash position of $149.5 million plus $76.8 million from a recent public offering.
Tenaya Therapeutics (TNYA) announced the appointment of Amy Burroughs to its Board of Directors, enhancing its leadership team as it advances its pipeline in heart disease therapies. Burroughs, who has over 20 years of experience in drug development, is expected to contribute to Tenaya’s mission of discovering and commercializing novel genetic therapies. This addition follows the departure of Eli Casdin, who stepped down to focus on other commitments after more than three years of service. Tenaya aims to solidify its position in the biotechnology sector.
Tenaya Therapeutics has received FDA orphan drug designation for its gene therapy candidate TN-401, targeted at treating genetic arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations. This designation, the first for a gene therapy for ARVC, provides access to development incentives. TN-401 is designed to deliver a healthy PKP2 gene copy via a single intravenous dose. The company plans to submit an IND application to the FDA in 2023, while also initiating a global study on ARVC mutation carriers to gather clinical data.